A Study of IMC-TR1 in Participants With Advanced Solid Tumors

Exclusion Criteria

• •Have clinically significant cardiac disease, including:
• •* Myocardial infarction within 6 months prior to study entry, unstable angina pectoris, congestive heart failure, or uncontrolled hypertension
• •* Major electrocardiogram (ECG) abnormalities
• •* Major abnormalities documented by echocardiography with Doppler
• •* Have known predisposing conditions that are consistent with development of aneurysms of the ascending aorta or aortic stress
• •* Have Corrected QT Interval (QTc interval) of \> 500 msec on screening ECG
• •Have other known serious pre-existing medical conditions
• •Have received prior investigational therapy targeting Transforming growth factor beta (TGFβ) or its receptors
• •Have a known sensitivity to monoclonal antibodies or other therapeutic proteins, to agents of similar biologic composition as IMC-TR1
• •Have a high risk of gastrointestinal bleeding, active inflammatory bowel disease, or chronic steroid use
• •Are currently using or has received a systemic thrombolytic agent within 28 days prior to enrollment
• •Are receiving:
• •* full-dose warfarin
• •* intravenous heparin or low-molecular-weight heparin
• •* chronic daily treatment with aspirin at a dose greater than 325 mg per day or nonsteroidal anti-inflammatory medications known to inhibit platelet function
• •Have evidence of retinal disease or are a monocular participant
• •Have received a solid organ transplant, bone marrow transplant or stem cell transplant
• •Have symptomatic central nervous system (CNS) malignancy or untreated metastasis
• •Have acute or chronic leukemia
• •Have a known active fungal, bacterial, and/or viral infection including human immunodeficiency virus or viral hepatitis requiring treatment
• •Has a positive fecal occult blood test within 14 days prior to enrollment